Antisense Phase II Clinical Trial now 50% enrolled and on track for completion
Published 21-JAN-2019 09:10 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Antisense Therapeutics (ASX:ANP) has provided a highly promising update on its Phase II clinical trial of its immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD).
The company has indicated that five patients are now enrolled in the nine patient trial, with four of these now being dosed with ANP’s ATL1102 treatment. The fifth patient has recently passed the eligibility criteria, and will commence their dosing schedule in early February.
No serious adverse events or affects have been reported to date during the trial, which is being conducted at the neuromuscular centre of the Royal Children’s Hospital in Melbourne (RCH) (which operates the largest DMD treatment clinic in the southern hemisphere).
About ATL1102
ATL1102 is an inhibitor of CD49d expression on certain immune cells (T cells). Scientific literature has reported that patients who possess a greater number of T cells with high levels of CD49d on their surface, experience more severe and rapid disease progression.
ATL1102 is being developed as a novel treatment for the inflammation that exacerbates muscle fibre damage in DMD patients, currently treated with corticosteroids. Unfortunately, corticosteroids have a range of serious side effects when used for extended periods, which is required in DMD patients.
The main objective of the trial pertain to the safety and tolerability of ATL1102, with the effectiveness of its ability to reduce inflammation, muscle damage and disease progression to also be assessed.
ANP remains on track to have nine patients enrolled into the trial and have their dosing complete in Q3 2019. Trial results will follow, however earlier study read outs are possible (because the trial is an open label study).
US based DMD group Parent Project Muscular Dystrophy (PPMD), whose advocacy efforts have secured hundreds of millions of dollars in funding and secured two FDA approvals, have incorporated details on the ATL1102 for DMD trial on their website (which can be found below).
Link: https://www.parentprojectmd.org/faqs/atl1102-cd49d-antisense-oligonucleotide/
PPMD’s efforts are focused on advancing care and treatments for DMD by leveraging US federal resources, building partnerships and creating regulatory procedures and infrastructure.
Since its inception in 2000, PPMD has invested over US$50 million into DMD research and therapy development and aid in leveraging over US$500 million dedicated for DMD.
ANP CEO Mark Diamond spoke on the clinical trial update, “We are very pleased to see the ATL1102 listing by PPMD, the most prominent US DMD advocacy group, as it significantly increases visibility and awareness of ANP’s DMD clinical development activities in the US, the world’s largest pharmaceutical market.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
